Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  API >  Antineoplastic agents >  Tinib Antineoplastic drugs >  Tandutinib

Tandutinib

Basic information Safety Supplier Related

Tandutinib Basic information

Product Name:
Tandutinib
Synonyms:
  • Tandutinib
  • 1-Piperazinecarboxamide, 4-(6-methoxy-7-(3-(1-piperidinyl)propoxy)-4-quinazolinyl)-N-(4-(1-methylethoxy)phenyl)-
  • 4-(6-Methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-yl)piperazine-1-carboxylic acid (4-isopropoxyphenyl)amide
  • Unii-E1io3icj9a
  • Tandutinib(CT 53518)
  • Tandutinib (MLN518)
  • CT53518; MLN518
  • Tandutinib(TINIBS)
CAS:
387867-13-2
MF:
C31H42N6O4
MW:
562.7
Product Categories:
  • Inhibitors
  • ZUBRIN
  • API
  • Intermediates & Fine Chemicals
  • Pharmaceuticals
  • Tyrosine Kinase Inhibitors
Mol File:
387867-13-2.mol
More
Less

Tandutinib Chemical Properties

Melting point:
177-178°C
Boiling point:
769.5±60.0 °C(Predicted)
Density 
1.213±0.06 g/cm3(Predicted)
storage temp. 
Sealed in dry,Store in freezer, under -20°C
solubility 
Chloroform (Slightly), Methanol (Slightly)
pka
13.39±0.70(Predicted)
form 
Solid
color 
White to Off-White
CAS DataBase Reference
387867-13-2(CAS DataBase Reference)
More
Less

Tandutinib Usage And Synthesis

Description

Tandutinib is a potent antagonist of platelet-derived growth factor receptor β (PDGFRβ), FLT3, and c-Kit (IC50 = 200, 220, and 170 nM, respectively). It less potently inhibits macrophage colony-stimulating factor 1 receptor (IC50 = 3.4 μM) and does not significantly inhibit other tyrosine or serine/threonine kinases. Tandutinib blocks the growth of cells expressing an internal tandem duplication within the juxtamembrane domain of the FLT3 receptor, found in some acute myelogenous leukemia cells. It also impairs the growth of colon cancer cells through its actions on the c-Kit receptor. Tandutinib reverses multidrug resistance in vitro by impairing the efflux activity of the multidrug resistance protein 7.

Chemical Properties

White Solid

Uses

An oral, small-molecule inhibitor of FLT3 for the treatment of AML (acute myelogenous leukemia) and other cancer indications. The drug exhibited limited activity as a single agent in phase I and II clinical trials in patients with AML and myelody

Uses

antipsoratic

Uses

An oral, small-molecule inhibitor of FLT3 for the treatment of AML (acute myelogenous leukemia) clinical trials in patients with AML and myelodysplastic syndrome, but displayed promising antileukemic activity (90% complete remissions) in a phase I/II trial in patients with newly diagnosed AML w hen administered in combination with cytarabine and daunorubicin.

Definition

ChEBI: An N-arylpiperazine that is piperazine in which the hydrogen attached to the nitrogen at position 1 is replaced by a 6-methoxy-7-[3-(piperidin-1-yl)propoxy]quinazolin-4-yl group, while the hydrogen attached to the nitrogen at position 4 s replaced by a (p-isopropoxyphenyl)aminocarbonyl group. Tandutinib is an inhibitor of tyrosine kinases FLT3, PDGFR and KIT.

target

c-Kit

References

[1] kelly lm1, yu jc, boulton cl, apatira m, li j, sullivan cm, williams i, amaral sm, curley dp, duclos n, neuberg d, scarborough rm, pandey a, hollenbach s, abe k, lokker na, gilliland dg, giese na. ct53518, a novel selective flt3 antagonist for the treatment of acute myelogenous leukemia (aml). cancer cell. 2002 jun;1(5):421-32.

TandutinibSupplier

Shanghai Jinyin Biological Technology Co., Ltd Gold
Tel
021-20986266 18019349802
Email
814527417@qq.com
Shanghai Boyle Chemical Co., Ltd.
Tel
Email
sales@boylechem.com
J & K SCIENTIFIC LTD.
Tel
010-82848833 400-666-7788
Email
jkinfo@jkchemical.com
Chembest Research Laboratories Limited
Tel
+86-21-20908456
Email
sales@BioChemBest.com
LGM Pharma
Tel
1-(800)-881-8210
Email
inquiries@lgmpharma.com